Vertex Pharmaceuticals announced its biggest M&A play yet Wednesday evening, acquiring Alpine Immune Sciences for $4.9 billion. The deal was unanimously approved by the board of directors at both ...

Vertex Pharmaceuticals is acquiring immune therapies developer Alpine Immune Sciences in a $4.9 billion deal whose centerpiece is a Phase 3-ready drug for a chronic kidney disorder with few treatment ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that three of its researchers have been awarded the 2024 Breakthrough Prize in Life Sciences “for developing ...

Vertex Pharmaceuticals announced Wednesday that it would acquire a Seattle biotechnology company focused on developing innovative immunotherapies for $4.9 billion in cash. The Boston-based drug ...

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up. The companies ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations ...

Google Cloud has enhanced its Vertex AI Search product with generative AI capabilities to support the healthcare and life sciences industries, the company announced Monday morning. Timed to coincide ...

Please provide your email address to receive an email when new articles are posted on . Vertex Pharmaceuticals will buy Alpine Immune Systems for $4.9 billion in cash. Alpine has a product in the ...

Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 billion, the companies announced Wednesday. It is the largest ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Wednesday announced that it has agreed to acquire Alpine Immune Sciences Inc. (ALPN), a biotechnology company focused on discovering and developing ...